Elisabetta Antonioli

7.8k total citations
56 papers, 3.3k citations indexed

About

Elisabetta Antonioli is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Elisabetta Antonioli has authored 56 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Genetics, 33 papers in Molecular Biology and 29 papers in Hematology. Recurrent topics in Elisabetta Antonioli's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Kruppel-like factors research (15 papers) and Multiple Myeloma Research and Treatments (14 papers). Elisabetta Antonioli is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Kruppel-like factors research (15 papers) and Multiple Myeloma Research and Treatments (14 papers). Elisabetta Antonioli collaborates with scholars based in Italy, United States and Germany. Elisabetta Antonioli's co-authors include Alessandro M. Vannucchi, Paola Guglielmelli, Tiziano Barbui, Alessandro Rambaldi, Guido Finazzi, Alberto Bosi, Alessandra Carobbio, Alessandro Pancrazzi, Ayalew Tefferi and Giovanni Barosi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Elisabetta Antonioli

52 papers receiving 3.3k citations

Peers

Elisabetta Antonioli
Elisabetta Antonioli
Citations per year, relative to Elisabetta Antonioli Elisabetta Antonioli (= 1×) peers Elisa Rumi

Countries citing papers authored by Elisabetta Antonioli

Since Specialization
Citations

This map shows the geographic impact of Elisabetta Antonioli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabetta Antonioli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabetta Antonioli more than expected).

Fields of papers citing papers by Elisabetta Antonioli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabetta Antonioli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabetta Antonioli. The network helps show where Elisabetta Antonioli may publish in the future.

Co-authorship network of co-authors of Elisabetta Antonioli

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabetta Antonioli. A scholar is included among the top collaborators of Elisabetta Antonioli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabetta Antonioli. Elisabetta Antonioli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martino, Massimo, Barbara Gamberi, Elisabetta Antonioli, et al.. (2024). Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?. Expert Review of Hematology. 17(7). 375–390. 3 indexed citations
2.
Fazio, Francesca, Maria Teresa Petrucci, Laura Corvatta, et al.. (2024). Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy. SHILAP Revista de lepidopterología. 5(3). 485–493. 1 indexed citations
3.
Vannucchi, Alessandro M., et al.. (2024). Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports. Cancer Reports. 7(10). 1 indexed citations
4.
Zampieri, Mattia, Marco Allinovi, Iacopo Olivotto, et al.. (2021). Ventricular tachyarrhythmias and sudden cardiac death in light‐chain amyloidosis: a clash of cardio‐toxicities?. British Journal of Haematology. 193(4). e27–e31. 5 indexed citations
5.
Loscocco, Giuseppe Gaetano, Elisabetta Antonioli, Ilaria Romano, et al.. (2021). Lenalidomide: A double‐edged sword for concomitant multiple myeloma and post‐essential thrombocythemia myelofibrosis. American Journal of Hematology. 96(6). 749–754. 2 indexed citations
6.
Finazzi, Guido, Alessandra Carobbio, J. Thiele, et al.. (2011). Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 26(4). 716–719. 131 indexed citations
7.
Barbui, Tiziano, Alessandra Carobbio, Francisco Cervantes, et al.. (2009). Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 115(4). 778–782. 196 indexed citations
8.
Vannucchi, Alessandro M., Paola Guglielmelli, Lisa Pieri, Elisabetta Antonioli, & Alberto Bosi. (2009). Treatment options for essential thrombocythemia and polycythemia vera. Expert Review of Hematology. 2(1). 41–55. 4 indexed citations
9.
Carobbio, Alessandra, Guido Finazzi, Elisabetta Antonioli, et al.. (2008). Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 112(8). 3135–3137. 79 indexed citations
10.
Vannucchi, Alessandro M., Elisabetta Antonioli, Paola Guglielmelli, Animesh Pardanani, & Ayalew Tefferi. (2008). Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 22(7). 1299–1307. 215 indexed citations
11.
Brodsky, Robert A., Neal S. Young, Elisabetta Antonioli, et al.. (2007). Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 111(4). 1840–1847. 457 indexed citations
12.
Ruggeri, Marco, Francesco Rodeghiero, Alberto Tosetto, et al.. (2007). Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 111(2). 666–671. 77 indexed citations
13.
Guglielmelli, Paola, Lorenzo Tozzi, Alessandro Pancrazzi, et al.. (2007). MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental Hematology. 35(11). 1708.e1–1708.e12. 61 indexed citations
14.
Vannucchi, Alessandro M., Elisabetta Antonioli, Paola Guglielmelli, et al.. (2007). Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia. 21(9). 1952–1959. 279 indexed citations
15.
Guglielmelli, Paola, Alessandro Pancrazzi, Gaetano Bergamaschi, et al.. (2007). Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation. British Journal of Haematology. 137(3). 244–247. 103 indexed citations
16.
Vannucchi, Alessandro M., Alessandro Pancrazzi, Costanza Bogani, Elisabetta Antonioli, & Paola Guglielmelli. (2006). A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia. 20(6). 1055–1060. 54 indexed citations
17.
Gianfaldoni, Giacomo, Francesco Mannelli, Michela Baccini, et al.. (2006). Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. British Journal of Haematology. 134(1). 54–57. 34 indexed citations
18.
Gianfaldoni, Giacomo, et al.. (2005). Chronic Relapsing Thrombotic Thrombocytopenic Purpura Successfully Treated with Rituximab: Case Report. Journal of Chemotherapy. 17(4). 449–451. 3 indexed citations
19.
Vannucchi, Alessandro M., Giuseppe Ficarra, Elisabetta Antonioli, & Alberto Bosi. (2005). Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. British Journal of Haematology. 128(6). 738–738. 88 indexed citations
20.
Vannucchi, Alessandro M., Alberto Grossi, Alessandro Pancrazzi, et al.. (2004). PRV‐1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. British Journal of Haematology. 127(2). 214–219. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026